This article was originally published in The Tan Sheet
Canadian Dermatology Association writes FDA in support of monograph status for Givaudan-Roure's sunscreen ingredient Parsol 1789. R. W. Danby, MD, chair of CDA's Sunscreen Product Education Program, states in a June 22 letter that since the UVA ingredient's Canadian approval in 1989, "there have been a relatively small number of cases of allergic sensitization" to Parsol 1789-containing products. He cited "only two cases" of such adverse reactions. CDA's cutaneous adverse reaction program, he added, "confirms the lack of significant" adverse events
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC